Studie - Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Review, H1 2012

Focal Segmental Glomerulosclerosis (FSGS) — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H1 2012', provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) therapeutic pipeline. This report provides information on the therapeutic development for Focal Segmental Glomerulosclerosis (FSGS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Focal Segmental Glomerulosclerosis (FSGS). 'Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Focal Segmental Glomerulosclerosis (FSGS).
- A review of the Focal Segmental Glomerulosclerosis (FSGS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Focal Segmental Glomerulosclerosis (FSGS) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Focal Segmental Glomerulosclerosis (FSGS) pipeline depth and focus of Focal Segmental Glomerulosclerosis (FSGS) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Focal Segmental Glomerulosclerosis (FSGS) Overview 6

Therapeutics Development 7

An Overview of Pipeline Products for Focal Segmental Glomerulosclerosis (FSGS) 7

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics under Development by Companies 9

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics under Investigation by Universities/Institutes 10

Late Stage Products 11

Comparative Analysis 11

Mid Clinical Stage Products 12

Comparative Analysis 12

Early Clinical Stage Products 13

Comparative Analysis 13

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics — Products under Development by Companies 14

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics — Products under Investigation by Universities/Institutes 15

Companies Involved in Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Development 16

Genzyme Corporation 16

Focal Segmental Glomerulosclerosis (FSGS) — Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Combination Products 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Drug Profiles 23

GC1008 - Drug Profile 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Cyclosporin - Drug Profile 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Mycophenolate Mofeti + Dexamethasone - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Mycophenolate Mofetil + Prednisolone - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Isotretinoin - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Adalimumab - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Avandia - Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics — Drug Profile Updates 34

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics — Discontinued Products 35

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Dormant Products 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 38

Disclaimer 38





List of Tables

Number of Products Under Development for Focal Segmental Glomerulosclerosis (FSGS), H1 2012 7

Products under Development for Focal Segmental Glomerulosclerosis (FSGS) — Comparative Analysis, H1 2012 8

Number of Products under Development by Companies, H1 2012 9

Number of Products under Investigation by Universities/Institutes, H1 2012 10

Comparative Analysis by Late Stage Development, H1 2012 11

Comparative Analysis by Mid Clinical Stage Development, H1 2012 12

Comparative Analysis by Early Clinical Stage Development, H1 2012 13

Products under Development by Companies, H1 2012 14

Products under Investigation by Universities/Institutes, H1 2012 15

Genzyme Corporation, H1 2012 16

Assessment by Monotherapy Products, H1 2012 17

Assessment by Combination Products, H1 2012 18

Assessment by Stage and Route of Administration, H1 2012 20

Assessment by Stage and Molecule Type, H1 2012 22

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics — Drug Profile Updates 34

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics — Discontinued Products 35

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics — Dormant Products 36





List of Figures

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS), H1 2012 7

Products under Development for Focal Segmental Glomerulosclerosis (FSGS) — Comparative Analysis, H1 2012 8

Products under Development by Companies, H1 2012 9

Products under Investigation by Universities/Institutes, H1 2012 10

Late Stage Products, H1 2012 11

Mid Clinical Stage Products, H1 2012 12

Early Clinical Stage Products, H1 2012 13

Assessment by Monotherapy Products, H1 2012 17

Assessment by Combination Products, H1 2012 18

Assessment by Route of Administration, H1 2012 19

Assessment by Stage and Route of Administration, H1 2012 20

Assessment by Molecule Type, H1 2012 21

Assessment by Stage and Molecule Type, H1 2012 22

• Growth Hormone Deficiency – Pipeline Review, H1 2013
• Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013
• Growth Disorders – Pipeline Review, H1 2013
• Kidney Fibrosis – Pipeline Review, H1 2013
• Urinary Incontinence – Pipeline Review, H1 2013
• Global Endocrinology Drugs Market 2012-2016
• Inguinal Hernia Global Clinical Trials Review, H1, 2013
• End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline Review, H2 2012
• Microalbuminuria – Pipeline Review, H2 2012
• Nocturia – Pipeline Review, H2 2012
• Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012
• Hypoparathyroidism – Pipeline Review, H2 2012
• Proteinuria – Pipeline Review, H2 2012
• Thyroid Gland Disorders – Pipeline Review, H2 2012
• Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H2 2012
• Hypothyroidism Global Clinical Trials Review, H2, 2012
• Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2012
• Other Genito Urinary Disorders – Pipeline Review, H2 2012
• Urinary Retention Global Clinical Trials Review, H2, 2012
• Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Review, H2 2012